Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Reexamination Certificate
1995-06-07
2004-10-19
Bansal, Geetha P. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
C424S137100, C424S184100, C424S143100, C424S155100, C530S387200, C530S387700, C530S388800, C530S388850, C514S885000
Reexamination Certificate
active
06805862
ABSTRACT:
BACKGROUND OF THE INVENTION
R24, an IgG3 mouse monoclonal antibody (mAb) raised against a human melanoma, recognizes the GD
3
ganglioside. The GD
3
ganglioside is abundantly expressed on most melanomas, however, expression of the GD
3
ganglioside on normal tissue is selective and occurs at low concentrations (1). Gangliosides are a subset of glycosphingolipids which in turn are a subset of glycolipids. Glycolipids, as their name implies, are sugar-containing lipids.
R24 comprises a known mixture of three variant antibody species (
FIG. 11
) designated V1-R24, V2-24, and R24. The V1-R24 and V2-R24 variants comprise one and two irrelevant antibody light chains, respectively; in contrast. R24 comprises relevant light chains. Generally, light and heavy antibody chains in combination effect specific antibody-antigen binding. However, antibodies comprising irrelevant antibody light chains, unlike antibodies comprising relevant antibody light chains, do not specifically bind an antigen.
In order to avoid confusion, the R24 variant from hereinafter will be referred to as “R24” and R24 comprising the three variant species will be referred to as the “R24 composition.” Each variant exhibits differences which imply that the GD
3
-binding region (also termed “paratope”) of V1-R24, V2-R24, and R24 are altered.
Anti-idiotypic monoclonal antibodies which mimic and possess the internal image of a saccharidic epitope have been developed (2). The saccharidic epitope is a tumor associated globoside, i.e. a glycolipid. However, these anti-idiotypic (monoclonal antibodies do not specifically mimic a glycosphingolipid, a ganglioside, or more particularly the GD
3
ganglioside. Additionally, these anti-idiotypic monoclonal antibodies are not directed against R24 or any antibodies which specifically bind a glycosphingolipid or a ganglioside, let alone the GD
3
ganglioside.
Mice have been primed against capsular antigens of pathogenic bacteria by administration of monoclonal anti-idiotypic antibodies which mimic the polysaccharide capsule of
E. coli
(a gram negative bacteria) (3). It is generally known that lipopolysaccharides (LPS) is a major component of the outer membrane of gram negative bacteria and is released when bacteria are lysed. LPS consists of a heteropolysaccharide chain linked covalently to a glycolipid. It is important to point out that although these monoclonal anti-idiotypic antibodies were used as a means to prime a subject against a LPS, there is no suggestion of generating monoclonal anti-idiotypic antibodies against R24 or any antibodies which would specifically bind glycosphingolipids or gangliosides, in particular the GD
3
ganglioside.
The GD
3
ganglioside is poorly immunogenic (1). Accordingly, the GD
3
ganglioside is an appealing target for cancer immunotherapy because of the commercial utility of designing molecules which would structurally mimic GD
3
and possess dramatically significant immunogenic properties.
SUMMARY OF THE INVENTION
The present invention also provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid and more specifically against a ganglioside. Additionally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier. Finally, this invention provides a method of generating the previously-identified anti-idiotypic antibody which comprises: (a) preparing an antibody; (b) purifying the antibody; (c) attaching the antibody onto a carrier so as to produce an immunogen; (d) combining the immunogen with a cytokine so as to produce a novel immunogen-cytokine combination; and (e) injecting the novel immunogen-cytokine combination into a mammal thereby producing the anti-idiotypic antibody.
REFERENCES:
patent: RE32833 (1989-01-01), Green et al.
patent: 4849509 (1989-07-01), Thurin et al.
patent: 4900547 (1990-02-01), Levy et al.
patent: 4918164 (1990-04-01), Hellstrom et al.
patent: 5126262 (1992-06-01), Matsui et al.
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5493009 (1996-02-01), Ferrone
patent: 5529922 (1996-06-01), Chapman et al.
patent: 5792455 (1998-08-01), Chapman et al.
patent: 0134868 (1985-03-01), None
patent: 0306995 (1989-03-01), None
patent: 0473721 (1998-12-01), None
patent: WO A 8706840 (1987-11-01), None
patent: WO A 8808429 (1988-11-01), None
patent: WO14104 (1990-11-01), None
Miller, Proc. 11thAnnual Cancer Symposium. Scripps Memorial Hospitals Cancer Center p. 3-5, 1987.*
Irie et al Advances in the Biology and Clinical Management of Melanoma 35thAnnual Clinical Conference & Twentyfourth Annual Special Pathology Program Nov. 20-23, 1991, pp. 46-47, 1991.*
Houghton et al PNAS vol. 82, pp. 1242-1246, Feb. (1985).*
Tsuchida et al, J. Natl Cancer Inst. Jan. (1987) vol. 78, p. 45-54.*
Vitetta et al. Science vol. 238, pp. 1098-1104, Nov. 20, 1987.*
Bucholtz Seminars in Oncol. SVurs. vol. 3, No. 1 pp. 67-73 (1989).*
Chapman, P.B., et al. (1993) “Use of BEC2 anti-idiotypic monoclonal antibody (MAb) to induce antibodies against GD3 ganglioside in melanoma patients”, Proc. Annu. Meet. Am. Soc. Clin. Oncol., 12:A1323 (Exhibit 3).
Chapman, P.B., et al., (1994) “Immunization of Melanoma Patients Against G-D3 Ganglioside With BEC2, an Anti-Idiotypic Monoclonal Antibody”,Cancer Biotherapy, 9(1):95-96, Abstract. (Exhibit 4).
Grant, S.C., et al., (1996) “Long Survival following Immunization with BEC2 plus BCG after Initial Therapy for Small Cell Lung Cancer (SCLC)”,Proc. Annu. Meet. Am. Soc. Clin. Oncol., 15:A1806. (Exhibit 5).
Mittleman, A., et al., (1992) “Human High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Induction of Humoral Anti-HMW-MAA Immunity and Prolongation of Survival in Patients with Stage IV Melanoma”,Proceedings of the National Academy of Sciences of the United States of America, 89(2):466-470. (Exhibit 6).
Mittleman, A., et al., (1990) “Anti-Idiotypic Monoclonal Antibodies in Patients with Malignant Melanoma Enhancement of Their Immunogenicity by Conjugates to KLH and BCG”,Clinical Research, 38(2), 549A, Abstract. (Exhibit 7).
Morrision et al., “Genetically Engineered Antibody Molecules and Their Application,”Annals of the New York Academy of Sciences, 507:187-198 (1987).
Real et al., “Surface Antigens of Melanomas and Melanocyets Defined by Mouse Monoclonal Antibodies: Specificity Analysis and Comparison of Antigen Expression in Cultured Cells and Tissues,”Cancer Research, 45: 4401-4411 (1985).
Tao et al., “Studies of Aglycosylated Chimeric Mouse-Human IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region,”The Journal of Immunology, 143:2595-2601 (1989).
Viale G., et al., “Anti-human Tumor Antibodies Induced In Mice And Rabbits By “Internal Image” Anti-idiotypic Monoclonal Immunoglobulins”,J. Immunology, Dec. 15, 1987, vol. 139, pp. 4250-4255.
Wei, W-Z., et al., “Improved Anti-tumor Reactivity With Monoclonal Anti-idiotypic Antibody Conjugated To Syngeneic Mouse Red Blood Cells”,J. Immunology Methods, 1989, vol. 122, pp. 227-234.
European Search Report, published Oct. 10, 1998 (Exhibit 1).
Chapman et al. “Pilot Trial of Anti-Idiotypic Monoclonal Antibody BEC2 in Patients with Metastatic Melanoma,”Proceedings of the American Association for Cancer Research, vol. 33:208 (1992) (Exhibit 2).
Soderstrom, T. et al. “TheEscherichia coliK1 Capsule Shares Antigenic Determinants with the Human Ganglioside GM3 and GD3”The New England Journal of Medicine, 310: 727-727 (1984) (Exhibit 3).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site Directed Mutagenesis of a Single Lysine Residue” Journal of Cell Biology, 111:2129-2138 (1990).
Chapman et al., “Anti-idiotype vaccines”,Biologic Therapy of Cancer Updates(1992) 2; 1-9 (review article).
Chapman, et al., (1993) “Use of BEC2 Anti-Idiotypic Monoclonal Antibody (Mab) To Induc
Chapman Paul B.
Houghton Alan N.
Bansal Geetha P.
Cooper & Dunham LLP
Sloan-Kattering Institute For Cancer Research
White John P.
LandOfFree
Anti-idiotypic antibody which induces an immune response... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-idiotypic antibody which induces an immune response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-idiotypic antibody which induces an immune response... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3277965